Selegiline is a monoamine oxidase-B (MAO-B) inhibitor used in dogs primarily for canine cognitive dysfunction syndrome (CDS), a progressive age-related condition that can affect sleep, orientation, social interaction, activity, house training and learning. The veterinary brand Anipryl is FDA-approved in the United States for control of clinical signs associated with canine cognitive dysfunction. It also carries an older approval for selected cases of uncomplicated pituitary-dependent hyperadrenocorticism, although trilostane is now the more established medical treatment for most dogs with Cushing’s disease.
Dog Medication Math Calculator
Enter your dog’s current body weight, then use only the dose already provided by your veterinarian or pharmacy label. The calculator converts lb/kg and can work out mg and liquid mL. It does not choose or recommend a dose.
Dose information from your veterinarian
Optional liquid conversion
Selegiline is not a sedative and it is not a general “senior dog vitamin.” Its effects involve brain monoamine metabolism, particularly dopamine. Because it changes neurotransmitter handling, its interaction profile matters: combining it with serotonergic antidepressants or tricyclic drugs can be dangerous.
What canine cognitive dysfunction looks like
CDS is often described through changes in disorientation, interactions, sleep-wake cycle, house soiling, activity, anxiety and learning. Owners may notice a dog getting stuck behind furniture, pacing at night, staring into space, seeming less interested in family, forgetting familiar routines or having accidents despite a lifetime of house training.
Those signs are not specific to cognitive decline. Pain, vision or hearing loss, urinary disease, kidney disease, endocrine disease, seizures, brain tumors and medication effects can all create similar behavior changes. A senior dog deserves a medical workup before new behavior is attributed to “old age.”
How selegiline works
Selegiline preferentially inhibits monoamine oxidase-B at usual canine doses. MAO-B breaks down dopamine and other monoamines in the brain. By reducing that breakdown, selegiline can increase dopaminergic activity in regions involved in learning and behavior.
Merck Veterinary Manual also notes potential antioxidant effects and reduction of free-radical load. The practical goal is not to reverse aging but to improve meaningful daily behaviors and quality of life in dogs with CDS.
What improvement may look like
Response is individual. Some owners notice better sleep, more normal interaction, improved orientation, fewer house-soiling episodes or less aimless pacing. Improvement may be partial rather than dramatic.
Keep a baseline list before treatment begins. If “better” is not defined, it can be hard to judge response several weeks later. A simple weekly record of nighttime waking, accidents, pacing, interaction and appetite is often more useful than a general impression.
Selegiline does not replace environmental support
Medication works best as part of a broader senior-dog plan. Predictable routines, easy access to water and toileting, non-slip flooring, night lights, gentle activity, food puzzles that are not frustrating, and keeping furniture layout stable can reduce confusion.
Dogs with arthritis or sensory loss may appear cognitively worse because movement, hearing or vision is impaired. Treating pain and making the environment easier to navigate can improve function even when CDS is also present.
Why morning administration is commonly used
FDA labeling for Anipryl recommends once-daily morning administration for CDS. Morning dosing fits the drug’s activating profile and may be less likely to interfere with nighttime rest in a dog already experiencing sleep-wake changes.
Follow the veterinary label rather than changing timing casually. If the dog becomes unusually restless or sleep worsens after treatment starts, report that pattern to the prescribing veterinarian.
Selegiline dosage by weight: Anipryl cognitive-dysfunction label
FDA approval information for Anipryl lists 0.5–1.0 mg/kg by mouth once daily, preferably in the morning, for canine cognitive dysfunction syndrome. That differs from the higher-dose protocol historically used for pituitary-dependent hyperadrenocorticism, so the indication must be clear before any dose is interpreted.
| Indication | FDA-approved canine guidance | Important distinction |
|---|---|---|
| Cognitive dysfunction syndrome | 0.5–1.0 mg/kg PO once daily, preferably in the morning | This is the dose context for senior-dog cognitive signs |
| Pituitary-dependent hyperadrenocorticism | Historically approved at a different, higher regimen | Do not transfer that regimen to cognitive dysfunction |
See the FDA approval summary for canine cognitive dysfunction. Selegiline is an MAO inhibitor, so interaction screening with SSRIs, TCAs and other serotonergic medicines remains essential.
Side effects to watch for
Possible adverse effects include gastrointestinal upset, restlessness, agitation, changes in sleep, reduced appetite, diarrhea or vomiting. Because CDS itself can cause pacing and sleep disturbance, timing relative to starting or increasing the medicine helps with interpretation.
New tremors, marked agitation, high body temperature, severe weakness, collapse or unusual neurologic signs require prompt assessment, especially if another psychoactive medicine may have been given.
Selegiline must not be mixed casually with SSRIs
This is one of the most important safety points. Merck states that selegiline should not be combined with serotonin reuptake inhibitors because serious drug interactions can occur. Fluoxetine is a particularly important example because it remains in the body for a long time after stopping.
If a dog has been taking fluoxetine, do not start selegiline until the veterinarian has provided an appropriate washout plan. The same principle applies in the reverse direction when switching from selegiline to another serotonergic drug.
Tricyclic antidepressants also matter
Clomipramine and other tricyclic antidepressants can interact dangerously with MAO inhibitors. A dog with separation anxiety may already be taking clomipramine, so a new CDS diagnosis requires medication review rather than simply adding selegiline.
Never combine these drugs because the behavior problem seems severe. The interaction can be more dangerous than the symptoms being treated.
Trazodone and other serotonergic medicines
Trazodone, some pain medicines and other behavior drugs can influence serotonin. The complete list should be reviewed before selegiline begins. The risk is not limited to drugs labeled “antidepressants.”
Tell the veterinarian about supplements too. Products marketed for calming or mood support may contain ingredients that affect monoamine pathways.
What serotonin toxicity can look like
Excess serotonergic activity can cause agitation, tremors, abnormal movements, rapid heart rate, high temperature, gastrointestinal signs and changes in mental status. Severe cases can be life-threatening.
If a dog receives selegiline together with a prohibited serotonergic medicine by mistake and develops concerning signs, seek urgent veterinary care and bring the medication containers.
Selegiline and pain management
Senior dogs with CDS often also have arthritis. Some analgesics can interact with monoamine oxidase inhibitors, and the safest pain plan may differ once selegiline is added.
Do not start leftover tramadol or another centrally acting pain medicine without review. The fact that it was previously prescribed to the same dog does not make the combination automatically safe now.
What if a dose is missed?
Do not double the next dose automatically. CDS treatment depends on long-term consistency rather than correcting one missed tablet with extra medication.
Use the missed-dose guide for general principles and ask the clinic if the dog has also changed other psychoactive medicines.
What if an extra dose is given?
An accidental extra dose can increase the risk of agitation, gastrointestinal signs, blood-pressure changes or neurologic effects. Contact the veterinarian or animal poison service with the tablet strength, amount involved, dog’s weight and every other medication being used.
Do not give a sedative, antidepressant or calming supplement to counteract the mistake unless a veterinarian specifically instructs you to do so.
How long before deciding whether it helps?
Behavioral response is not always immediate. FDA approval studies and clinical experience support allowing enough time to judge meaningful changes rather than stopping after only a few days. Owners should monitor specific behaviors over several weeks and review them with the veterinarian.
If there is no useful improvement, the next step is not automatically a higher dose. The dog may need reassessment for pain, sensory loss, neurologic disease, urinary disease or another cause of the observed behavior.
When “cognitive decline” is actually pain
An older dog that paces, sleeps poorly, hesitates on stairs or withdraws socially may be uncomfortable rather than cognitively impaired. Arthritis, dental pain and spinal disease are common in the same age group as CDS.
A careful examination and pain history belong in the diagnostic process. Treating pain can improve sleep and interaction and can make the true cognitive component easier to see.
Vision and hearing loss can mimic disorientation
A dog that startles when approached, fails to respond to familiar cues or gets stuck in a dark room may have declining hearing or vision. Sensory loss can coexist with cognitive dysfunction and make it look worse.
Simple environmental changes such as night lights, tactile cues, non-slip paths and avoiding frequent furniture rearrangement can improve safety without changing medication.
House-soiling needs a medical check
New indoor urination can occur with CDS, but urinary tract infection, kidney disease, diabetes mellitus, Cushing’s disease, urinary incontinence and increased urine production from medications are common alternatives. New fecal accidents can also reflect gastrointestinal disease or reduced mobility.
Do not assume every accident is “senility.” Urinalysis, bloodwork and a mobility assessment may reveal a more treatable cause.
Sleep-wake changes
Dogs with CDS may sleep more during the day and pace or vocalize at night. Selegiline may help some dogs, but nighttime activity can also reflect pain, anxiety, the need to urinate, sensory decline or seizures.
Track when waking occurs and what the dog does. Repeated episodes at the same time, circling, staring or unusual motor behavior may justify neurologic evaluation rather than simply increasing a behavior medication.
Selegiline and canine Cushing’s disease
Anipryl also has an FDA approval for selected dogs with uncomplicated pituitary-dependent hyperadrenocorticism. That indication is separate from cognitive dysfunction. Current endocrine references place trilostane as the treatment of choice for most dogs with Cushing’s disease, while selegiline has a more limited role.
A senior dog can have both CDS and Cushing’s disease. Increased thirst, panting, appetite and house-soiling should not be attributed to cognitive decline until endocrine disease has been considered.
Why pituitary-dependent Cushing’s is a special indication
Selegiline’s Cushing’s indication applies to selected uncomplicated pituitary-dependent disease, not adrenal-tumor Cushing’s. The drug’s action on central dopamine pathways is the rationale, but response is less predictable than with direct adrenal steroid-synthesis suppression.
If Cushing’s signs progress despite selegiline, the veterinarian may recommend a different endocrine treatment rather than continuing indefinitely without objective improvement.
Do not use selegiline as a general anti-anxiety drug
Although selegiline affects brain monoamines and has behavioral effects, it is not a substitute for fluoxetine, clomipramine or situational anxiety medicines in the typical treatment of separation anxiety, noise fear or generalized anxiety.
Using it casually for anxiety can create a difficult interaction problem later if an SSRI or tricyclic is actually needed.
Liver and kidney considerations
Senior dogs are more likely to have chronic organ disease, and selegiline is metabolized to active compounds. Baseline bloodwork can be useful before treatment, especially when the dog is taking several other medications.
A major change in appetite, vomiting, weakness or neurologic status after starting treatment deserves review rather than being blamed automatically on aging.
Medication reconciliation is essential in senior dogs
Older dogs may be taking heart medicines, pain medicines, supplements, sedatives and behavior drugs from more than one clinic. Before selegiline is prescribed, the veterinarian should see the entire list.
Keep a written list with exact names, strengths and timing. “A calming tablet at night” is not specific enough to screen for an important interaction.
Can selegiline be stopped suddenly?
Do not stop or restart long-term psychoactive medication casually. Although selegiline does not create the same dependence concerns as some sedatives, transitions to or from serotonergic drugs require planning because of interaction risk.
If the medicine is not helping or appears to cause adverse effects, call the prescribing veterinarian for a discontinuation and washout plan.
Diet, enrichment and cognitive support
Merck notes that specific diets and supplements may improve cognitive signs or slow decline in some dogs. Medium-chain triglycerides, antioxidants and certain nutraceutical combinations are among approaches studied in canine aging.
These measures are not interchangeable with selegiline, but they can be part of a multimodal plan. Choose products based on evidence and the dog’s medical conditions rather than stacking many supplements at once.
How to judge quality of life
Improvement should matter to the dog and household. Useful outcomes include sleeping more normally, navigating familiar spaces, interacting voluntarily, maintaining house training and enjoying routine activities.
If severe anxiety, nighttime distress, incontinence or disorientation continues despite treatment, discuss whether pain control, environmental support or a different diagnosis has been overlooked.
Before anesthesia or procedures
Tell the anesthetic team that the dog takes selegiline. Some anesthetic, analgesic and serotonergic drugs may interact with monoamine oxidase inhibition, so the medication list can influence the perioperative plan.
Do not stop the drug at an arbitrary interval before surgery. The veterinarian should decide whether a washout is needed and how long it should be.
What to record at home
Choose a handful of behaviors that matter: nighttime waking, accidents, getting stuck, response to family, pacing, appetite and ability to follow familiar routines. Record frequency rather than only impressions.
That record helps determine whether the medicine is genuinely improving function and whether changes correlate with dose timing or another new medication.
Questions to ask the veterinarian
Ask which signs support a diagnosis of CDS, what other causes have been excluded, which behaviors should improve if selegiline works, and how long to assess response before making a decision.
Review every antidepressant, anxiety medicine, pain medicine and supplement before the first dose. If a serotonergic drug was recently stopped, ask exactly how long the washout should be.
Reliable references
The Merck Veterinary Manual psychotropic-drug review lists selegiline among monoamine oxidase inhibitors used for cognitive dysfunction in aging dogs. Merck’s canine behavior chapter discusses cognitive dysfunction, environmental support and multimodal treatment.
FDA approval records for Anipryl document its use for control of clinical signs associated with canine cognitive dysfunction and selected pituitary-dependent Cushing’s disease.
Why reassessment still matters after a good response
A dog may respond well for months and later develop new pacing, house-soiling or nighttime waking because CDS has progressed or because a new medical problem has appeared. Do not assume every later change means selegiline has “stopped working.” Senior dogs remain vulnerable to pain, urinary disease, endocrine disease, vision loss and neurologic disorders.
Periodic senior examinations and routine laboratory screening help keep the original diagnosis honest. A medication that once improved cognition should not become a reason to overlook new disease.
Making the household routine easier
Use the same feeding, walking and bedtime cues each day when practical. Place water, bedding and toilet access where the dog can reach them without stairs or slippery surfaces. Gentle predictability reduces the amount of new learning required and can make medication response easier to judge.
These changes are inexpensive, low risk and often improve quality of life even when the dog remains on selegiline long term.
Bottom line
Selegiline can help some dogs with canine cognitive dysfunction by improving brain monoamine signaling and reducing selected age-related behavior changes. The diagnosis should come after medical causes of confusion, accidents and sleep disturbance have been considered.
Its most important practical safety issue is drug interaction. Do not combine selegiline casually with fluoxetine, clomipramine, trazodone or other serotonergic medicines, and plan any transition with the prescribing veterinarian.
DogMedsHub provides source-backed canine medication guidance and does not diagnose, prescribe or replace veterinary care.
